Protara Therapeutics Liabilities 2024

Protara Therapeutics Aktienanalyse

What does Protara Therapeutics do?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Protara Therapeutics's Liabilities

Protara Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Protara Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Protara Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Protara Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Protara Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Protara Therapeutics stock

What is the level of liabilities of Protara Therapeutics this year?

Protara Therapeutics has a debt balance of 10.63 M USD this year.

What were the liabilities of Protara Therapeutics compared to the previous year?

The liabilities of Protara Therapeutics have increased by -5.06% dropped compared to the previous year.

What are the consequences of high debt for investors of Protara Therapeutics?

High liabilities can pose a risk for investors of Protara Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Protara Therapeutics?

Low liabilities mean that Protara Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Protara Therapeutics affect the company?

An increase in liabilities of Protara Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Protara Therapeutics affect the company?

A decrease in the liabilities of Protara Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Protara Therapeutics?

Some factors that can influence the liabilities of Protara Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Protara Therapeutics so important for investors?

The liabilities of Protara Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Protara Therapeutics take to modify the liabilities?

To change its liabilities, Protara Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Protara Therapeutics pay?

Over the past 12 months, Protara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protara Therapeutics?

The current dividend yield of Protara Therapeutics is .

When does Protara Therapeutics pay dividends?

Protara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protara Therapeutics?

Protara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protara Therapeutics located?

Protara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protara Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Protara Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Protara Therapeutics in the year 2023?

In the year 2023, Protara Therapeutics distributed 0 USD as dividends.

In which currency does Protara Therapeutics pay out the dividend?

The dividends of Protara Therapeutics are distributed in USD.